Summary of COVID-19 aviptadil studies
Hide extended summaries
RCT 196 patients with critical COVID-19 respiratory failure showing improved survival but no significant difference in the primary endpoint of "alive and free of respiratory failure at day 60" with IV aviptadil.
Aug 2022, Critical Care Medicine, https://journals.lww.com/10.1097/CCM.0000000000005660, https://c19p.org/youssef
461 patient aviptadil late treatment RCT: 6% higher mortality (p=0.71) and 10% lower progression (p=0.54).
RCT 461 hospitalized patients with COVID-19-associated respiratory failure showing no significant difference in outcomes with aviptadil treatment.
Sep 2023, The Lancet Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S2213260023001479, https://c19p.org/brown4
118 patient aviptadil late treatment RCT: 79% worse recovery (p=0.02).
RCT 118 patients showing significantly worse recovery with aviptadil treatment.
Mar 2022, NCT04488081, https://www.prnewswire.com/news-releases/i-spy-covid-trial-sponsored-by-quantum-leap-healthcare-collaborative-suggests-no-clinical-benefit-with-addition-of-nebulized-zyesami-aviptadil-when-given-by-mouth-inhalation-in-critically-ill-patients-with-covid-19-301514508.html, https://c19p.org/gibbs
1. Youssef et al., The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial
196 patient aviptadil late treatment RCT: 35% lower mortality (p=0.04) and 20% lower progression (p=0.27).RCT 196 patients with critical COVID-19 respiratory failure showing improved survival but no significant difference in the primary endpoint of "alive and free of respiratory failure at day 60" with IV aviptadil.
Aug 2022, Critical Care Medicine, https://journals.lww.com/10.1097/CCM.0000000000005660, https://c19p.org/youssef
461 patient aviptadil late treatment RCT: 6% higher mortality (p=0.71) and 10% lower progression (p=0.54).
RCT 461 hospitalized patients with COVID-19-associated respiratory failure showing no significant difference in outcomes with aviptadil treatment.
Sep 2023, The Lancet Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S2213260023001479, https://c19p.org/brown4
118 patient aviptadil late treatment RCT: 79% worse recovery (p=0.02).
RCT 118 patients showing significantly worse recovery with aviptadil treatment.
Mar 2022, NCT04488081, https://www.prnewswire.com/news-releases/i-spy-covid-trial-sponsored-by-quantum-leap-healthcare-collaborative-suggests-no-clinical-benefit-with-addition-of-nebulized-zyesami-aviptadil-when-given-by-mouth-inhalation-in-critically-ill-patients-with-covid-19-301514508.html, https://c19p.org/gibbs
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.